Mirum Pharmaceuticals, Inc. (MIRM) — Stock Score Summary

Mirum Pharmaceuticals, Inc. (MIRM) has a MoatMap StockRank of 68/100 based on Quality (41/100), Value (39/100), and Momentum (72/100) factor scores. The current signal is BUY. While Mirum has promising rare disease therapeutics, it operates outside our core macro themes and lacks the established, high-ROIC compounding profile we require for a concentrated book.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for rare liver diseases, primarily targeting cholestatic liver conditions in pediatric and adult patients. The company's pipeline and approved product (Livmarli) address significant unmet medical needs, leveraging a deep understanding of bile acid biology. Mirum benefits from its specialized focus and orphan drug designations, providing market exclusivity and a clear path to serving specific patient populations.

Key Financial Metrics

Price$95.48
Market Cap$6.1B
P/E (Forward)-165.75
Price/Book23.24
Return on Equity-335.8%
Return on Invested Capital-1.1%
Debt/Equity133.52
Gross Margin81.4%
Operating Margin-39.5%
Revenue Growth43.3%
Free Cash Flow$167M

Mirum Pharmaceuticals, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Mirum Pharmaceuticals, Inc.’s (MIRM) StockRank?
MoatMap’s StockRank for Mirum Pharmaceuticals, Inc. (MIRM) is 68/100, with a Buy signal. It is a composite of Quality (41), Value (39), and Momentum (72) factor ranks across MoatMap’s 19,000+ stock universe.
Does Mirum Pharmaceuticals, Inc. have an economic moat?
Mirum Pharmaceuticals, Inc. (MIRM) has a Quality factor score of 41/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Mirum Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for Mirum Pharmaceuticals, Inc. (MIRM) is Buy, based on a StockRank of 68/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Mirum Pharmaceuticals, Inc. in?
Mirum Pharmaceuticals, Inc. (MIRM) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksMIRM deep dive reportAI ChampionsHow we score stocksSense-check another stock